Starlix (nateglinide), a new oral tablet for type 2 diabetes

February 2001

Novartis is now marketing Starlix (nateglinide), a new oral tablet for type 2 diabetes.

Think of it as a shorter-acting Prandin (repaglinide).

Both meds are taken before meals to stimulate insulin release...but Starlix has a shorter duration.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

laws to help reduce medication errors
Diabetes Starlix (nateglinide), a new oral tablet for type 2 diabetes
Diabetes The Health Care Financing Administration (HCFA) has FINALLY said how much and who will get paid for diabetes education
Dermatology Protopic, a new NON-STEROIDAL ointment for eczema
Women's Health Femara (letrozole) or Arimidex (anastrozole) for breast cancer
Women's Health the safety of misoprostol use during labor and delivery
Substance Use Disorder drugs of abuse
Infectious Diseases new immunization schedule for children
Infectious Diseases PEG-Intron, a longer-acting form of Intron-A for treating hepatitis C
Gastroenterology too many hospital patients get acid-suppressing drugs
Gastroenterology new chewable Lactobacillus tablet called Probiotica
Cardiology new IV anticoagulant, Angiomax (bivalirudin)
Migraine ACE inhibitor to PREVENT migraines
Migraine valproate to TREAT migraines
whether inhaled steroids are useful for treating COP
Diabetes statins reduce the risk of developing diabetes
Practice new drugs approved by the FDA in 2000